Tech Company Inital Public Offerings
Olema Oncology IPO
Headquartered in San Francisco, Olema Oncology is now a public company.
Transaction Overview
Company Name
Announced On
11/18/2020
Transaction Type
IPO
Amount
$209,000,000
Proceeds Purpose
Per the firm's most recent regulatory filing, it plans to use the net proceeds as follows:approximately $40.0 million to $60.0 million to complete our ongoing Phase 1/2 monotherapy clinical trial;approximately $10.0 million to $20.0 million to advance OP-1250 through our planned Phase 1b combination trials with CDK4/6i and PI3Ka; andthe remainder for other ongoing research and development activities, and for other general corporate purposes, including working capital, operating expenses and capital expenditures.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
665 3rd St. 250
San Francisco, CA 94107
USA
San Francisco, CA 94107
USA
Phone
Undisclosed
Website
Email Address
Overview
Olema Oncology (Nasdaq: OLMA) is a biopharmaceutical company developing innovative targeted therapies for women's cancers. The Company's lead program, OP-1250, a potential best-in-class complete estrogen receptor antagonist (CERAN), is in development to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sean Bohen
Chief Medical Officer
Pamela Klein
Chief Operating Officer
Shane Kovacs
Chief Scientific Officer
Peter Kushner
Chief Technical Officer
Cyrus Harmon
VP - Bus. Development
Kinney Horn
VP - Bus. Development
David Myles
VP - General Counsel
John Moriarty
Browse more venture capital transactions:
Prev: 11/18/2020: ActivTrak venture capital transaction
Next: 11/18/2020: OpenPhone venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from company press releases and news coverage. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs